Expand EYPT Menu
EYPT MENU

EYPT Latest Press Releases

-- February 5, 2025 --

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints Globe Newswire 7:00 AM

-- January 30, 2025 --

EyePoint to Present at Guggenheim SMID Cap Biotech Conference Globe Newswire 7:00 AM

-- January 16, 2025 --

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- January 13, 2025 --

EyePoint Provides Company Update and Anticipated Development Milestones for 2025 Globe Newswire 7:00 AM

-- January 8, 2025 --

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors Globe Newswire 7:00 AM

-- December 17, 2024 --

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 16, 2024 --

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- December 4, 2024 --

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration Globe Newswire 7:00 AM

-- November 18, 2024 --

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- November 7, 2024 --

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments Globe Newswire 7:00 AM

-- November 4, 2024 --

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- October 31, 2024 --

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares Globe Newswire 4:00 PM

-- October 29, 2024 --

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering Globe Newswire 9:47 PM

-- October 28, 2024 --

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock Globe Newswire 5:14 PM
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Globe Newswire 7:00 AM

-- October 24, 2024 --

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration Globe Newswire 7:00 AM

-- October 16, 2024 --

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- September 16, 2024 --

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 7:00 AM